focus -WSS

focus

author：focus 2025-10-01 00:46:46 - browse：527

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Popular nasal decongestant doesn't actually relieve congestion

Wikipedia

WSS

FDA panel endorses Alnylam’s heart drug — after picking it apart

New Covid vaccine is recommended for everyone 6 months or older

Biotech startup Celsius cuts 75% of staff ahead of first trial start

H.R. 3 is the wrong path to lower drug costs

Diverse clinical trials: Why aren’t we there yet?

Walmart eyes Medicare Advantage provider ChenMed

knowledge

focus

focus

Walensky prepares to leave CDC — and Congress — behind

Will the IRA bring competition to the biologics market?

BioMarin wins approval for gene therapy to treat hemophilia A

WATCH: Why do bright lights make us see spots?

New air purifier tech could be key to improving indoor air quality

A controversial new treatment promises to make little people taller

Walensky prepares to leave CDC — and Congress — behind

Chris Christie meets with Zelenskyy during Ukraine trip

Trump demands the U.S. pay no more for drugs than other countries … again

Pharma showers House GOP doctor with campaign cash

leisure time

Pig kidney works a record two months in donated body

Heart disease in astronauts blamed on cosmic radiation

'Null' research findings aren't empty of meaning. Let's publish them

Physicians aren't 'burning out.' They're suffering from moral injury

Study links childhood stress with decline in older age

FDA scientists endorse Pfizer/BioNTech Covid

Wikipedia

explore

leisure time

entertainment